Everest Medicines Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Everest Medicines hat ein Gesamteigenkapital von CN¥5.0B und eine Gesamtverschuldung von CN¥480.6M, was einen Verschuldungsgrad von 9.7% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen CN¥5.8B bzw. CN¥804.1M.

Wichtige Informationen

10.9%

Verhältnis von Schulden zu Eigenkapital

CN¥539.24m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CN¥2.35b
Eigenkapital	CN¥4.97b
Gesamtverbindlichkeiten	CN¥804.10m
Gesamtvermögen	CN¥5.77b

Jüngste Berichte zur Finanzlage

Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?

Apr 27

Recent updates

Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?

Apr 27

Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 31

A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

Jan 31

A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

Sep 26

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 1952Die kurzfristigen Aktiva des Unternehmens (CN¥2.5B) übersteigen seine kurzfristigen Passiva (CN¥300.1M).

Langfristige Verbindlichkeiten: 1952Die kurzfristigen Vermögenswerte des Unternehmens (CN¥2.5B) übersteigen seine langfristigen Verbindlichkeiten (CN¥504.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 1952 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 1952 hatte vor 5 Jahren ein negatives Eigenkapital, ist jetzt aber positiv und hat sich somit verbessert.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: Obwohl 1952 unrentabel ist, verfügt es über eine ausreichende Cash-Runway für mehr als 3 Jahre, wenn es seinen derzeitigen positiven freier Cashflow beibehält.

Vorhersage Cash Runway: 1952 ist unrentabel, verfügt aber über eine ausreichende Liquiditätsreserve für mehr als drei Jahre, da der freie Cashflow positiv ist und um 12.4% pro Jahr wächst.

Everest Medicines Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?

Recent updates

Now 24% undervalued

Consensus EPS estimates fall by 38%, revenue upgraded

First half 2024 earnings: Revenues in line with analyst expectations

Now 22% undervalued after recent price drop

New minor risk - Profitability

No longer forecast to breakeven

Everest Medicines Limited to Report First Half, 2024 Results on Aug 27, 2024

Now 21% undervalued after recent price drop

Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis

Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration

Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

Everest Medicines Limited, Annual General Meeting, Jun 28, 2024

Now 24% overvalued after recent price rise

Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China

Everest Medicines Announces New Drug Application Approval of Velsipity® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau

Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients

Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?

Now 22% overvalued after recent price rise

Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings released

Forecast to breakeven in 2026

Now 23% overvalued after recent price rise

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

Consensus revenue estimates increase by 28%

Everest Medicines Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Now 25% overvalued after recent price rise

Everest Medicines Limited Announces Board Changes

Now 23% undervalued after recent price drop

A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

Consensus revenue estimates increase by 17%

Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023

Everest Medicines Limited Announces Directorate Changes

Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients

Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024

Calliditas’ Partner Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy

National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China

Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

Everest Medicines Limited Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients

Consensus revenue estimates decrease by 16%, EPS upgraded

First half 2023 earnings released: CN¥1.40 loss per share (vs CN¥2.26 loss in 1H 2022)

Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon(R) for the Treatment of Primary IgA Nephropathy

Everest Medicines Limited to Report First Half, 2023 Results on Aug 24, 2023

Everest Medicines Announces Completion of Patient Enrollment in Nefecon®? China Open Label Extension Study

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA in China

Everest Medicines Appoints Mike Berry as Chief Technology Officer

New major risk - Share price stability

Everest Medicines Limited, Annual General Meeting, Jun 29, 2023

Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia

Consensus revenue estimates increase by 151%

Consensus revenue estimates decrease by 17%

No longer forecast to breakeven

Consensus estimates of losses per share improve by 91%

Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary Iga Nephropathy

Consensus EPS estimates fall by 593%

Everest Medicines Limited Announces Board Changes

Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China

Consensus revenue estimates fall by 28%

Everest Medicines Aims to Initiate Clinical Trials and File an Emergency Use Authorization Application in 2023 in China for Its Lead mRNA Candidate

Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy

Less than half of directors are independent

Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy

Everest Medicines Announces Approval of XERAVA in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections

Forecast to breakeven in 2022

Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001

Everest Medicines Appoints Rogers Yongqing Luo as an Executive Director

Everest Medicines Limited Announces Resignation of Kerry Blanchard as A Member of the Board of Directors

Consensus revenue estimates increase by 99%

Everest Medicines Limited to Report First Half, 2022 Results on Aug 24, 2022

Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan

Everest Medicines Announces Approval of Trodelvy in China for Second-Line Metastatic Triple-Negative Breast Cancer

Less than half of directors are independent

Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis